Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

The Cyclosporine-A Treatment does not have Harmful Effect on the Linear Growth of Pediatric Patients with Steroid-dependent and Steroid-resistant Nephrotic Syndrome

  • Lee, Sang Soo (Department of Pediatrics, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Ji Hoon (Department of Pediatrics, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Chung Ho (Department of Nuclear Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Cho, Byoung-Soo (MIRAE-iNG Kidney Center) ;
  • Kim, Deog Yoon (Department of Nuclear Medicine, School of Medicine, Kyung Hee University) ;
  • Hong, Il Ki (Department of Nuclear Medicine, School of Medicine, Kyung Hee University) ;
  • Suh, Jin-Soon (Department of Pediatrics, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2016.07.13
  • Accepted : 2016.10.10
  • Published : 2016.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study was performed to evaluate the effects of cyclosporine-A (CsA) on linear growth in pediatric patients with steroid-dependent (SDNS) or resistant nephrotic syndrome (SRNS). Methods: Thirty-five pediatric patients with SDNS or SRNS undergoing glucocorticoid (GC) and/or CsA treatment were retrospectively reviewed. Seventeen patients were treated with GC alone and 18 were treated with GC and CsA. The cumulative doses of GC and CsA were quantified (mg/kg/day). Linear growth during the follow-up period was defined as the difference in Z-score between the initial and final height according to the follow-up period (${\Delta}$ height Z score/year). The associations between linear growth and clinical parameters were analyzed. Results: The linear growth of patients in the two groups was not significantly different (P=0.262). The ${\Delta}$ height Z score/year did not show a significant correlation with the cumulative doses of CsA, but was negatively correlated with the cumulative dose of GC and positively correlated with the Z score for height at the time of diagnosis. Conclusion: In children with SDNS or SRNS undergoing GC therapy, added CsA treatment may not have harmful effects on linear growth.

Keywords

References

  1. Motoyama O, Iitaka K. Final height in children with steroid-sensitive nephrotic syndrome. Pediatr Int 2007;49:623-5. https://doi.org/10.1111/j.1442-200X.2007.02429.x
  2. Gulati S, Sharma RK, Gulati K, Singh U, Srivastava A. Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. Nephrol Dial Transplant 2005;20:1598-603. https://doi.org/10.1093/ndt/gfh809
  3. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int 2008;73:1167-73. https://doi.org/10.1038/ki.2008.24
  4. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, et al. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol 2012;7:1576-83. https://doi.org/10.2215/CJN.00110112
  5. Freundlich M. Bone mineral content and mineral metabolism during cyclosporine treatment of nephrotic Syndrome. J Pediatr 2006;149:383-9. https://doi.org/10.1016/j.jpeds.2006.04.060
  6. Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global O. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013;28:415-26. https://doi.org/10.1007/s00467-012-2310-x
  7. Lombel RM, Hodson EM, Gipson DS, Kidney Disease: Improving Global O. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 2013;28:409-14. https://doi.org/10.1007/s00467-012-2304-8
  8. Seo JY, Cho YG, Kang JH, Hur YI, Park HA, Kim KW, et al. New diagnostic criteria for obesity and overweight in Korean children and adolescents using 2007 Korean National Growth Charts. Obes Res Clin Pract 2013;7:e182-9. https://doi.org/10.1016/j.orcp.2011.12.001
  9. Kano K, Nishikura K, Hoshi M, Yamada Y, Arisaka O. Linear growth of low-dose cyclosporin A therapy in children with steroid-dependent nephrotic syndrome. Nephron 2001;87:293-4. https://doi.org/10.1159/000045933
  10. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol 2015;30:459-68. https://doi.org/10.1007/s00467-014-2955-8
  11. Leroy V, Baudouin V, Alberti C, Guest G, Niaudet P, Loirat C, et al. Growth in boys with idiopathic nephrotic syndrome on longterm cyclosporin and steroid treatment. Pediatr Nephrol 2009;24:2393-400. https://doi.org/10.1007/s00467-009-1266-y
  12. Ribeiro D, Zawadynski S, Pittet LF, Chevalley T, Girardin E, Parvex P. Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome. Eur J Pediatr 2015;174:911-7. https://doi.org/10.1007/s00431-014-2479-z
  13. Olney RC. Mechanisms of impaired growth: effect of steroids on bone and cartilage. Horm Res 2009;72 Suppl 1:30-5. https://doi.org/10.1159/000229761
  14. Klaus G, Jux C, Fernandez P, Rodriguez J, Himmele R, Mehls O. Suppression of growth plate chondrocyte proliferation by corticosteroids. Pediatr Nephrol 2000;14:612-5. https://doi.org/10.1007/s004670000344
  15. Dong F, Ren J. Insulin-like growth factors (IGFs) and IGF-binding proteins in nephrotic syndrome children on glucocorticoid. Pharmacol Res 2003;48:319-23. https://doi.org/10.1016/S1043-6618(03)00182-8